The innovative molecular diagnostic device for rapid testing at the Point-of-Care.

BIOPIX-T, which was founded in 2019 and has its headquarters in Heraklion, Crete, aims to revolutionize molecular diagnostics at the Point-Of-Care and Home-Testing environments. Their flagship product is a mobile COVID-19 detection device, called Iris, which can identify the presence of the virus in a sample in just half an hour. The device, which functions just like a mini laboratory, is expected to be launch on the market in 2021. Created using 3D printing technology, Iris is backed by €2.4 million of EU funding.

MedTech, Healthcare, Diagnostic device
Between €1 million-€ 2.5 million

Articles about BIOPIX-T:

💡 You’re a corporate or investor and looking for startups that are innovating in the same market as BIOPIX-T? We’re happy to assist you with our Startup Sourcing service.